Physician profile
Jan W Davis
NPI 1821171786
$89,999.56
in general payments reported to CMS, 2019-2025
64 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $7,188 · 2023: $5,452 · 2024: $31K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $9,580 · Food and Beverage: $8,298 · Consulting Fee: $7,380 · Honoraria: $1,657 · Education: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,450.00 |
| Travel and Lodging | $9,580.35 |
| Food and Beverage | $8,297.57 |
| Consulting Fee | $7,380.00 |
| Honoraria | $1,656.71 |
| Education | $495.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $34,160.08 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals Lp | $23,626.33 | 2021-2025 | Datroway, Enhertu, Lynparza |
| Karyopharm Therapeutics INC. | $9,311.48 | 2021-2024 | Xpovio |
| Glaxosmithkline, LLC. | $4,619.27 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $2,986.92 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Uk Limited | $2,965.26 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $2,263.34 | 2023-2025 | |
| Accord Healthcare, INC. | $1,656.71 | 2024 | |
| Astellas Pharma US INC | $655.55 | 2021-2024 | Padcev, Xospata |
| Janssen Biotech, INC. | $624.54 | 2022-2024 | Darzalex, Tecvayli, Imbruvica |
| Genzyme Corporation | $528.47 | 2021-2024 | |
| Beigene USA, INC. | $455.75 | 2022-2024 | Brukinsa |
| Genentech USA, INC. | $432.95 | 2021-2024 | Polivy, Lunsumio, Phesgo |
| Seagen INC. | $397.08 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Coherus Oncology, INC. | $366.44 | 2024 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.